Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 3 (2006), Issue 11 (November)

  1. Long-term outcome among men with conservatively treated localised prostate cancer.
    Br J Cancer, 95(9): 1186-94. [Abstract] [Full-text]
  2. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
    J Natl Cancer Inst, 98(21): 1521-7. [Abstract] [Full-text]
  3. Recreational physical activity and risk of prostate cancer: A prospective population-based study in Norway (the HUNT study).
    Int J Cancer, 119(12): 2943-7. [Abstract] [Full-text]
  4. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cancer Res, 66(21): 10613-20. [Abstract] [Full-text]
  5. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Cancer Res, 66(21): 10594-602. [Abstract] [Full-text]
  6. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
    Cancer Res, 66(21): 10513-6. [Abstract] [Full-text]
  7. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.
    Cancer Res, 66(21): 10449-59. [Abstract] [Full-text]
  8. Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk.
    Cancer Res, 66(21): 10302-7. [Abstract] [Full-text]
  9. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Cancer Res, 66(21): 10242-6. [Abstract] [Full-text]
  10. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
    J Androl, 27(6): 725-8. [Abstract] [Full-text]
  11. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
    J Med Genet, 43(11): 863-6. [Abstract] [Full-text]
  12. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    J Urol, 176(6): 2701-5. [Abstract] [Full-text]
  13. Radical prostatectomy after previous prostate surgery: clinical and functional outcomes.
    J Urol, 176(6): 2459-63; discussion 2463. [Abstract] [Full-text]
  14. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?
    J Urol, 176(6): 2453-8; discussion 2458. [Abstract] [Full-text]
  15. Age stratified functional outcomes after laparoscopic radical prostatectomy.
    J Urol, 176(6): 2448-52. [Abstract] [Full-text]
  16. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
    J Urol, 176(6): 2443-7. [Abstract] [Full-text]
  17. Characteristics of patients with familial versus sporadic prostate cancer.
    J Urol, 176(6): 2438-42; discussion 2442. [Abstract] [Full-text]
  18. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
    J Urol, 176(6): 2432-7. [Abstract] [Full-text]
  19. Comparison of methods for calculating prostate specific antigen velocity.
    J Urol, 176(6): 2427-31; discussion 2431. [Abstract] [Full-text]
  20. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.
    J Urol, 176(6): 2383-5. [Abstract] [Full-text]
  21. Management of high risk metastatic prostate cancer: the case for novel therapies.
    J Urol, 176(6): S76-80; discussion S81-2. [Abstract] [Full-text]
  22. The case for early chemotherapy for the treatment of metastatic disease.
    J Urol, 176(6): S72-5. [Abstract] [Full-text]
  23. The case for secondary hormonal therapies in the chemotherapy age.
    J Urol, 176(6): S66-71. [Abstract] [Full-text]
  24. High risk biochemical relapse and the timing of androgen deprivation therapy.
    J Urol, 176(6): S61-5. [Abstract] [Full-text]
  25. Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure.
    J Urol, 176(6): S57-60; discussion S55-6. [Abstract] [Full-text]
  26. Bone related events in high risk prostate cancer.
    J Urol, 176(6): S50-4. [Abstract] [Full-text]
  27. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.
    J Urol, 176(6): S47-9. [Abstract] [Full-text]
  28. The case for systemic therapy alone for prostate cancer.
    J Urol, 176(6): S42-6. [Abstract] [Full-text]
  29. Management of locally advanced prostate cancer: past, present, future.
    J Urol, 176(6): S34-41. [Abstract] [Full-text]
  30. The case for adjuvant therapy for prostate cancer.
    J Urol, 176(6): S30-3. [Abstract] [Full-text]
  31. Initial therapy with radical prostatectomy for high risk localized prostate cancer.
    J Urol, 176(6): S27-9; discussion S25-6. [Abstract] [Full-text]
  32. Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification.
    J Urol, 176(6): S21-4; discussion S25-6. [Abstract] [Full-text]
  33. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
    J Urol, 176(6): S16-20. [Abstract] [Full-text]
  34. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    J Urol, 176(6): S11-5. [Abstract] [Full-text]
  35. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.
    J Cell Physiol, 210(1): 111-21. [Abstract] [Full-text]
  36. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
    Int J Cancer, 120(1): 170-4. [Abstract] [Full-text]
  37. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
    Int J Cancer, 120(1): 160-9. [Abstract] [Full-text]
  38. Targeting prostate cancer with radiolabelled bombesins.
    Cancer Imaging, 6: 153-7. [Abstract] [Full-text]
  39. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Biochem Biophys Res Commun, 351(3): 658-63. [Abstract] [Full-text]
  40. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Cancer Res, 66(22): 11077-83. [Abstract] [Full-text]
  41. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
    Cancer Res, 66(22): 11047-54. [Abstract] [Full-text]
  42. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway.
    Cancer Res, 66(22): 11039-46. [Abstract] [Full-text]
  43. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer.
    Cancer Res, 66(22): 10953-8. [Abstract] [Full-text]
  44. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Cancer Res, 66(22): 10919-28. [Abstract] [Full-text]
  45. Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3.
    Cancer Res, 66(22): 10878-84. [Abstract] [Full-text]
  46. Imaging mitogen-activated protein kinase function in xenograft models of prostate cancer.
    Cancer Res, 66(22): 10778-85. [Abstract] [Full-text]
  47. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
    Cancer Res, 66(22): 10683-90. [Abstract] [Full-text]
  48. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Cancer Res, 66(22): 10658-63. [Abstract] [Full-text]
  49. PSA screening among elderly men with limited life expectancies.
    JAMA, 296(19): 2336-42. [Abstract] [Full-text]
  50. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
    JAMA, 296(19): 2329-35. [Abstract] [Full-text]
  51. Patient and treatment factors associated with complications after prostate brachytherapy.
    J Clin Oncol, 24(33): 5298-304. [Abstract] [Full-text]
  52. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells.
    Oncogene, 25(55): 7311-23. [Abstract] [Full-text]
  53. Tumor escape mechanisms in prostate cancer.
    Cancer Immunol Immunother, 56(1): 81-7. [Abstract] [Full-text]
  54. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
    Cancer, 107(11): 2628-36. [Abstract] [Full-text]
  55. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Cancer, 107(11): 2597-603. [Abstract] [Full-text]
  56. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
    J Clin Oncol, 24(34): 5408-13. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

Surviving Prostate Cancer without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle

Surviving Prostate Cancer without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle